Key result
Antiangiogenic or antivascular therapies may attenuate the growth of Ewing sarcoma, as supported by preclinical models and early clinical data.
Why the study?
Do antiangiogenic or antivascular therapies attenuate the growth of Ewing sarcoma?
Do antiangiogenic or antivascular therapies attenuate the growth of Ewing sarcoma?
This review highlights the potential of antiangiogenic and antivascular therapies as a treatment approach for Ewing sarcoma based on preclinical and early clinical data.
Answers are grounded in this paper and cite their sources.
Does not support changing practice in Ewing sarcoma; leaves open further evaluation of antiangiogenic therapies in trials.
Ewing sarcoma is the second most common type of bone cancer in children and young adults. In recent years, the mechanisms by which these tumors develop and maintain their vascular supply have been elucidated. Additional work has demonstrated that inhibition of angiogenic pathways or disruption of established vasculature can attenuate the growth of Ewing sarcoma mouse xenografts. Early clinical data suggest that these results also may extend to patients with Ewing sarcoma who are treated with antiangiogenic or antivascular therapies. For the current review, the authors summarized the available data supporting this approach.
No takes yet. Share an insight, caveat, or question.
DuBois et al. (2009) conducted a review in Ewing sarcoma. Antiangiogenic or antivascular therapies was evaluated. Antiangiogenic or antivascular therapies may attenuate the growth of Ewing sarcoma, as supported by preclinical models and early clinical data.
Synapse has enriched 10 related papers. Consider them for comparative context: